return
  • Patient-centred treatment support is an important element of TB control and the prevention of MDR-TB and should be provided to all patients.

  • Regular monitoring is necessary to determine the progress and outcome of all TB treatment, and ensure that the patient completes the entire course of TB treatment with prompt ancillary treatment of any adverse effects.

  • In general, sputum is collected for follow-up examination at the end of the initial phase, just before the patient completes 5 months of treatment, and in the last week of treatment. This will vary by treatment regimen.

  • A minority of TB patients treated with regimens using first line drugs experience adverse effects. As regimens use second-line drugs for treatment of drug-resistant TB, the number of adverse effects may increase.
forward